Thematische Bibliographien / Anticancer chemotherapy

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte

Auswahl der wissenschaftlichen Literatur zum Thema „Anticancer chemotherapy“

Autor: Grafiati
Veröffentlicht am 28. Juni 2021
Zuletzt aktualisiert am 1. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Anticancer chemotherapy" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Anticancer chemotherapy"

1

Hayashi, S., S. Maruoka, N. Takahashi und S. Hashimoto. „Carotidynia after anticancer chemotherapy“. Singapore Medical Journal 55, Nr. 09 (September 2014): e142-e144. http://dx.doi.org/10.11622/smedj.2014127.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kvolik, S., L. Glavas-Obrovac, K. Sakic, D. Margaretic und I. Karner. „Anaesthetic implications of anticancer chemotherapy“. European Journal of Anaesthesiology 20, Nr. 11 (11.07.2005): 859–71. http://dx.doi.org/10.1017/s026502150300139x.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Kvolik, S., L. Glavas-Obrovac, K. Sakic, D. Margaretic und I. Karner. „Anaesthetic implications of anticancer chemotherapy“. European Journal of Anaesthesiology 20, Nr. 11 (November 2003): 859–71. http://dx.doi.org/10.1097/00003643-200311000-00002.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

F. Goncalves, R., G. Kriechammer und M. P.M. Marques. „MGBG in Combined Anticancer Chemotherapy“. Letters in Drug Design & Discovery 8, Nr. 10 (01.12.2011): 897–903. http://dx.doi.org/10.2174/157018011797655197.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Kratz, Felix, Ivonne A Müller, Claudia Ryppa und André Warnecke. „Prodrug Strategies in Anticancer Chemotherapy“. ChemMedChem 3, Nr. 1 (11.01.2008): 20–53. http://dx.doi.org/10.1002/cmdc.200700159.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Kris, M. G., Fausto Roila, Pieter H. M. De Mulder und Michel Marty. „Delayed emesis following anticancer chemotherapy“. Supportive Care in Cancer 6, Nr. 3 (27.04.1998): 228–32. http://dx.doi.org/10.1007/s005200050158.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Kris, M. G., K. M. W. Pisters und L. Hinkley. „Delayed emesis following anticancer chemotherapy“. Supportive Care in Cancer 2, Nr. 5 (September 1994): 297–300. http://dx.doi.org/10.1007/bf00365581.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Hennes, Emily R., Michael Reed, Mary Mably, Jason Jared, Jason J. Bergsbaken, Dustin Deming, Natalie Callander und Ruth O’Regan. „Implementation of a chemotherapy stewardship process“. American Journal of Health-System Pharmacy 77, Nr. 15 (04.07.2020): 1243–48. http://dx.doi.org/10.1093/ajhp/zxaa157.

Der volle Inhalt der Quelle
Annotation:
Abstract Purpose To design and implement a chemotherapy stewardship process to optimize the location of chemotherapy administration in an effort to decrease the number of inappropriate inpatient anticancer regimen administrations and decrease institutional costs associated with inpatient administration. Summary As the costs of anticancer agents continue to rise, it is crucial that multidisciplinary efforts are aimed at managing anticancer medication utilization; this is especially important for high-cost medications, medications whose use requires increased monitoring due to safety concerns, and medications that do not exert effects quickly and, as such, can be more appropriately administered in the outpatient setting. It is imperative that pharmacists play a role in managing chemotherapy medication utilization, as pharmacists provide expertise in formulary management, a vast knowledge of financial impact and reimbursement processes, and clinical knowledge that can help predict the expected effectiveness and adverse effects of each anticancer regimen. Our institution sought to develop and implement a multidisciplinary chemotherapy stewardship program targeting the optimization of site of anticancer agent administration with a goal of decreasing both cost and inappropriate utilization of high-cost, high-risk anticancer agents. Conclusion Implementation of a chemotherapy stewardship service may decrease the number of inappropriate inpatient anticancer regimen administrations and decrease inpatient resource use, thereby decreasing costs to institutions. The concept of a chemotherapy stewardship process was well received by multidisciplinary healthcare colleagues, and a collaborative approach should be used to design and implement such processes.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Ben Kridis, W., A. Khanfir und M. Frikha. „ACUTE PANCREATITIS INDUCED BY ANTICANCER CHEMOTHERAPY“. Acta Clinica Belgica 68, Nr. 4 (Juli 2013): 309–10. http://dx.doi.org/10.2143/acb.3351.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Ma, Yuting, Oliver Kepp, François Ghiringhelli, Lionel Apetoh, Laetitia Aymeric, Clara Locher, Antoine Tesniere et al. „Chemotherapy and radiotherapy: Cryptic anticancer vaccines“. Seminars in Immunology 22, Nr. 3 (Juni 2010): 113–24. http://dx.doi.org/10.1016/j.smim.2010.03.001.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Anticancer chemotherapy"

1

Fryatt, Tara. „Quinolinequinones as bioreductive anticancer agents“. Thesis, University of Exeter, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.302535.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ward, T. H. „Bioreductive anticancer drugs : a comet study on mechanisms and DNA damage“. Thesis, University of Salford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.245022.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Roffey, Jonathan R. A. „The synthesis of indole containing anticancer compounds“. Thesis, Loughborough University, 1996. https://dspace.lboro.ac.uk/2134/10935.

Der volle Inhalt der Quelle
Annotation:
The concept of bioreductive prodrug chemotherapy is introduced in chapter 1. Tumour cell hypoxia is a significant factor in limiting tumour growth control with conventional radiotherapy and some chemotherapeutic agents. Following therapy these cells can repopulate and cause a relapse of the cancer. On the other hand, hypoxia is unique to tumours, and is therefore potentially exploitable. Bioreductive prodrugs are compounds in which a oxygen inhibited redox-based bioactivation step triggers a reaction leading to a lethal intermediate. The concept of bioreductive DNA alkylators and DNA topoisomerase 11 inhibitors is discussed. The synthesis of model thiazolylindole compounds based on the natural product BE \0988 are discussed in chapter 2. Two strategies were employed for the construction of the thiazolylindoles: the Hantzsch reaction; and nucleophilic substitution on 2-bromothiazole by an indolyl anion. The synthesis of thiazolylindolequinone compounds are discussed in chapter 3. The quinone C(5) position of the thiazolylindolequinone analogues was elaborated to provide a series of cyclic and acyclic C(5)-amino derivatives. Synthetic strategies towards the synthesis of indole-2-carboxylates are discussed in chapter 4. The Moody-Rees and Cadogan-Sundberg reactions were employed to provide a synthesis of the useful highly substituted indole [154]. The Brederek imidazole reaction (i.e., the reaction of a amidine and a-halo ketone) is discussed in chapter 5. Application of the Brederek reaction was employed towards the construction of the bisindole imidazole natural compounds, the nortopsentins. The biological properties of the compounds of the compounds synthesised are discussed in chapter 6. The compounds were tested for DNA topoisomerase 11 inhibitory activity and cytotoxicity under a hypoxic environment.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Lant, Neil Joseph. „The synthesis and evaluation of anti-melanoma drugs“. Thesis, University of Glasgow, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341748.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Croughton, Karen. „Novel pharmacology of the lipophilic antifolate methylbenzoprim“. Thesis, University of Nottingham, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368236.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Rivero-Müller, Adolfo. „Speciation and reactivity of the antineoplastic copper-based compound : casiopeina II“. Thesis, University of Surrey, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.301319.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Stow, Martin William. „Molecular analysis of verapamil hypersensitive multidrug resistant hamster cell lines“. Thesis, University of York, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.258425.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Highfield, Jacqueline Ann. „The synthesis and testing of novel anticancer agents related to bleomycin“. Thesis, Brunel University, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.263514.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Nuthalapati, Silpa. „PRECLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF NEW ANTICANCER AGENTS FOR BRAIN TUMOR CHEMOTHERAPY“. Diss., Temple University Libraries, 2012. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/181390.

Der volle Inhalt der Quelle
Annotation:
Pharmaceutical Sciences
Ph.D.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults for which overall prognosis remains poor despite recent treatment advances, thus emphasizing the need for developing effective therapeutic agents. Styryl sulfones belong to a class of non-ATP competitive antineoplastic agents in early stage clinical trials. Detailed investigation of the pharmacokinetics (PKs) and pharmacodynamics (PDs) of novel agents in the preclinical stage plays a pivotal role in drug development that could be applied to guide clinical trials. The main goal of the project was to undertake comprehensive PK and PD evaluation of new agents for brain tumor therapy and in the process establish a PK/PD strategy for the development of such novel agents. The current project was aimed to evaluate the potential of a styryl benzyl sulfone compound, ON01910.Na, as a chemotherapeutic agent for the treatment of GBMs using PK/PD approaches. First, the systemic pharmacokinetics of ON01910 was characterized following single dose intravascular administration of ON01910.Na in healthy mice over a 50-fold dose range of 5 mg/kg - 250 mg/kg. Secondly, an evaluation of the brain and brain tumor disposition of ON01910 was conducted in an orthotopic U87 glioma model in mice using a steady-state dosing regimen, and, in addition, using the same brain tumor model its pharmacodynamic and antiangiogenic activity were determined following multiple dosing. ON01910 exhibited nonlinear pharmacokinetics in the dose range of 50 mg/kg - 250 mg/kg. It showed inadequate brain and brain tumor penetration and insignificant antiangiogenic and antiproliferative activity. The limited brain tumor penetration and activity of ON01910 in the intracerebral glioma model led to the evaluation of ON013105, a prodrug of its more lipophilic anticancer congener, ON013100. A similar PK/PD approach as for ON01910.Na was applied wherein systemic pharmacokinetic properties of ON013105 and its active form, ON013100 in healthy mice, as well as an analysis of their brain and brain tumor distribution following steady-state dosing regimen were determined following administration of prodrug. The active form, ON013100 showed appreciable brain and brain tumor penetration while the prodrug did not. Subsequent pharmacodynamic investigations conducted in vitro identified phosphorylated-ERK (pERK) as a PD marker. To assess time-dependent PK/PD characteristics, mice bearing intracerebral U87 glioma were administered ON013105 at 100 mg/kg intravenously and plasma, brain and brain tumor concentrations of ON013105 and its active form, ON013100 were quantitated as well as tumoral pERK levels. Further, a PK-PD model was developed that characterized plasma, brain and brain tumor concentration-time profiles of ON013105 and ON013100 and tumoral pERK levels. In summary, a PK/PD-driven approach was applied to evaluate and select novel compounds that may have potential in the treatment of brain tumors. The progression of studies yielded one compound, ON013100 that possessed favorable brain tumor distribution and showed PD activity that warrant continued evaluation.
Temple University--Theses
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Page, Simon Matthew. „Ruthenium anticancer complexes : a targeted approach to enzyme inhibition“. Thesis, University of Cambridge, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608027.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Anticancer chemotherapy"

1

Wani, Mohmmad Younus, und Manzoor Ahmad Malik. Gold and its Complexes in Anticancer Chemotherapy. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6314-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Macromolecular anticancer therapeutics. New York: Springer Verlag, 2009.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Laurell, Göran. Ototoxicity of the anticancer drug cisplatin: Clinical and experimental aspects. Stockholm, Sweden: Distributed by Almqvist & Wiksell Periodical Co., 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Avendaño, Carmen. Medicinal chemistry of anticancer drugs. Amsterdam: Elsevier, 2008.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

J, Houghton Peter, und Houghton Janet A, Hrsg. Preclinical and clinical modulation of anticancer drugs. Boca Raton: CRC Press, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Lipp, H. P. Prevention and management of anticancer drug toxicity: The significance of clinical pharmacokinetics. Jena: Univ.-Verlag, 1995.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

International, Interface of "Clinical and Laboratory Responses to Anticancer Drugs" (1st 1989 Villejuif France). Anticancer drugs : proceedings of the first International Interface of "Clinical and Laboratory Responses to Anticancer Drugs," March 13th-15th, 1989, Villejuif, France =: Médicaments anticancéreux : actes de la première confrontation internationale des "Réponses cliniques et expérimentales aux médicaments anticancéreux" 13-15 Mars 1989, Villejuif, France. Paris: INSERM, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

International Interface of "Clinical and Laboratory Responses to Anticancer Drugs" (1st 1989 Villejuif, France). Anticancer drugs: Proceedings of the first International Interface of "Clinical and Laboratory Responses to Anticancer Drugs," March 13th-15th, 1989, Villejuif, France = Médicaments anticancéreux : actes de la première confrontation internationale des "Réponses cliniques et expérimentales aux médicaments anticancéreux," 13-15 Mars 1989, Villejuif, France. Herausgegeben von Lampidis T. J, Robert Jacques M. D, Tapiero H und Institut national de la santé et de la recherche médicale (France). Paris, France: Editions INSERM ; London : J. Libbey Eurotext, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Zhong yao kang ai huo xing cheng fen: Anticancer active components in TCM. Beijing: Ke xue chu ban she, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

P, Hacker Miles, Lazo John S und Tritton Thomas R, Hrsg. Organ directed toxicities of anticancer drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, Burlington, Vermont, USA, June 4-6, 1987. Boston: Nijhoff, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Anticancer chemotherapy"

1

Schabel, F. M. „Rationale for Perioperative Anticancer Treatment“. In Perioperative Chemotherapy, 1–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-82432-6_1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Stone, Jeff, und Susan M. Blaney. „Intrathecal Chemotherapy“. In Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 289–306. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-734-5_18.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Wani, Mohmmad Younus, und Manzoor Ahmad Malik. „Anticancer Metal Complexes“. In Gold and its Complexes in Anticancer Chemotherapy, 35–39. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6314-4_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Kris, Mark G., Fausto Roila, Pieter H. M. De Mulder und Michel Marty. „Delayed Emesis Following Anticancer Chemotherapy“. In Perugia Consensus Conference on Antiemetic Therapy, 45–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72137-3_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Wani, Mohmmad Younus, und Manzoor Ahmad Malik. „Non-platinum Anticancer Agents“. In Gold and its Complexes in Anticancer Chemotherapy, 51–68. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6314-4_6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Wani, Mohmmad Younus, und Manzoor Ahmad Malik. „Platinum-Based Anticancer Agents“. In Gold and its Complexes in Anticancer Chemotherapy, 41–49. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6314-4_5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

van der Hoop, Roland Gerritsen, Lisa M. DeAngelis und Jerome B. Posner. „Neurotoxicity of Combined Radiation and Chemotherapy“. In Neurological Adverse Reactions to Anticancer Drugs, 45–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76142-3_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Brown, J. Martin, und Bradly G. Wouters. „Does Apoptosis Contribute to Tumor Cell Sensitivity to Anticancer Agents?“ In Apoptosis and Cancer Chemotherapy, 1–19. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-720-8_1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Haefner, Burkhard. „Targeting NF-κB in Anticancer Adjunctive Chemotherapy“. In The Link Between Inflammation and Cancer, 219–45. Boston, MA: Springer US, 2006. http://dx.doi.org/10.1007/0-387-26283-0_10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Wani, Mohmmad Younus, und Manzoor Ahmad Malik. „Mechanisms of Action of Anticancer Gold Complexes“. In Gold and its Complexes in Anticancer Chemotherapy, 159–70. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6314-4_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Anticancer chemotherapy"

1

Sundriyal, Deepak, Parmod Kumar, Yeswanth Gogisetti und Amit Sehrawat. „Weekly Etoposide and Platinum in Small-Cell Lung Cancer: Hope and Scope for Fragile Patients“. In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735372.

Der volle Inhalt der Quelle
Annotation:
Abstract Introduction Small-cell lung cancer (SCLC) is an aggressive and chemo-sensitive disease. Many patients present in an advanced stage and with a poor performance status (PS). In such a condition, the treatment dilemma due to poor condition advocates alternative treatment approach rather than standard chemotherapy. One way of usual practice is to split the chemotherapy into a weekly schedule. However, there is limited data regarding the actual benefit of weekly chemotherapy. We hypothesize that a weekly chemotherapy with etoposide/platinum combination will be feasible and safe in patients of advanced-stage SCLC with poor PS. Objectives This study was aimed to determine whether weekly etoposide/platinum chemotherapy is a safe option for patients with advanced stage, poor PS, and SCLC who are otherwise unfit for systemic anticancer therapy. Materials and Methods We retrospectively analyzed the data of SCLC patients presented to our center from July 2018 to September 2020. We analyzed that treatment, survival, and clinical benefit data. We also analyzed the benefit of weekly etoposide/platinum in otherwise unfit for chemotherapy. Results One hundred and fifty patients of lung cancer presente to our department between July 2018 and September 2020; SCLC constituted 34% (53 cases). In SCLC patients, the median overall survival was 2.5 months. Fourteen (26%) patients with SCLC were unable to start any oncological intervention. Ten (19%) patients could receive only one cycle of standard 3 weekly chemotherapy. Five patients with an advanced-stage SCLC and an ECOG-PS of 4, otherwise unfit for any systemic anticancer therapy, were started on weekly chemotherapy with etoposide (60–80 mg/m2) and carboplatin (AUC 2). Four patients demonstrated a partial response (PR) while one demonstrated stable disease (SD) after 9 weeks of therapy. Improvement in PS was noted in all patients. Median progression-free survival (PFS) and overall survival (OS) were 137 and 164 days, respectively. Two patients died of disease progression, one died of massive pulmonary embolism, while two were alive and continuing on the same protocol. Conclusion The weekly etoposide and platinum chemotherapy is a practical and feasible treatment option in patients who are otherwise fragile and unfit for standard-dose chemotherapy.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Salehi, Hamideh, Siham Al-Arag, Elodie Middendorp, Csilla Gergley und Frederic Cuisinier. „Stem cells as anticancer drug carrier to reduce the chemotherapy side effect“. In SPIE BiOS, herausgegeben von Daniel L. Farkas, Dan V. Nicolau und Robert C. Leif. SPIE, 2017. http://dx.doi.org/10.1117/12.2251994.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Sukkurwala, Abdul Qader, Mickaël Michaud, Isabelle Martins und Guido Kroemer. „Abstract 2262: Contribution of autophagy in anticancer immune response induced by chemotherapy“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2262.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Chentoufi, M. Alami, M. Benabbes, S. Bennis und B. Meddah. „5PSQ-072 Tolerance profile of platinum salts in anticancer chemotherapy: a prospective study“. In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.426.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Nagasaki, Yukio, Yuki Ozaki und Toru Yoshitomi. „Abstract 2900: Redox nanoparticle enhances effect of anticancer chemotherapy and suppresses cardio-toxicity“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2900.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Teo, Ka Yaw, und Bumsoo Han. „Freezing-Assisted Intracellular Drug Delivery to Multi-Drug Resistant Cancer Cells“. In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192373.

Der volle Inhalt der Quelle
Annotation:
The efficacy of chemotherapy is significantly impaired by multi-drug resistance (MDR) of cancer cells. The mechanism of MDR is associated with the overexpression of certain ATP-binding cassette protein transporters in plasma membranes. These transporters actively keep intracellular drug concentration below the cell-killing threshold by extruding cytotoxic drugs. Various strategies to overcome MDR have been proposed and have shown promising results at the laboratory level. However, pharmacokinetic alteration of co-administered anticancer agents reduces their clinical effectiveness. This leads to increased toxicity and undesirable side effects at effective concentrations [1]. Hence, a clinically feasible strategy to overcome the phenomenon of MDR is highly desired.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Hernandes, Camila, Bruna da Silva, Maria de Fatima Guarrido Klingbeil, Monica Beatriz Mathor, Ana Maria Soares Pereira und Patricia Severino. „Abstract 5456: Avoiding chemotherapy resistance in squamous cell carcinomas: anticancer activities of terpenoids and their impact on the regulation of microRNAs“. In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5456.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Cowell, Jessica, Susan J. Zimmerman, Mathieu Marrela, Ping Jiang, Peter J. Houghton, Michael J. LaBarre, Daniel C. Maneval, Curtis B. Thompson und Xiaoming Li. „Abstract 2463: PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms’ xenograft model“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2463.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Su, Xiulan, Chao Dong, Liya Su, Jialing Zhang, Xuemei Wang, Xia Bai, Hongwei Cui und Zhong Chen. „Abstract 2056: Anticancer bioactive peptide potentiates cisplatin chemotherapy efficacy to improve the quality of life in xenografted nude mice bearing human gastric cancer.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2056.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Grouix, Brigitte, Lilianne Geerts, Kathy Hince, Nathalie Julien, Marie-Eve Fafard, Liette Gervais, François Sarra-Bournet et al. „Abstract 3534: PBI-1402, a first-in-class erythropoiesis regulating agent, possesses differentiation properties and demonstrates synergistic anticancer activity in combination with chemotherapy“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3534.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Anticancer chemotherapy" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie